The Cooper Companies is trading 15.56% down at $53.66 after its September 9, 2026, third-quarter report missed revenue expectations and reduced fiscal 2026 revenue and adjusted-profit forecasts. - The company's decision to retain its CooperSurgical unit following a strategic review also weighed heavily on shares, as the market had anticipated a potential divestiture. - CooperVision organic growth stalled amid distributor inventory reductions, impacting results and future outlook. - Fourth-quarter earnings guidance also fell below analyst consensus, contributing to investor disappointment.